Medtronic delivered 8.4% reported revenue growth and 5.8% organic growth in fiscal 2026, with Q4 revenue of $9.8B exceeding guidance. The company increased its dividend for the 49th consecutive year and completed strategic M&A transactions including CathWorks acquisition while filing for FDA approval of Hugo RAS system.